Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (161-170 of 168) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 168 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
The Journal of Clinical Investigation|March 10, 2021
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responsesFan Huang, Christophe Gonçalves, Margarita Bartish, et al.
Cancer Research|May 12, 2021
The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast CancerQianyu Guo, Margarita Bartish, Christophe Gonçalves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine|July 6, 2023
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, John G Lenehan, Wilson H Miller, et al.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Science Immunology|April 1, 2022
Spatially mapping the immune landscape of melanoma using imaging mass cytometryDan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Pageof 17

Showing results (161-170 of 168) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 168 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
The Journal of Clinical Investigation|March 10, 2021
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responsesFan Huang, Christophe Gonçalves, Margarita Bartish, et al.
Cancer Research|May 12, 2021
The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast CancerQianyu Guo, Margarita Bartish, Christophe Gonçalves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine|July 6, 2023
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, John G Lenehan, Wilson H Miller, et al.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Science Immunology|April 1, 2022
Spatially mapping the immune landscape of melanoma using imaging mass cytometryDan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Pageof 17